Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N1YF
|
|||
| Former ID |
DNCL001801
|
|||
| Drug Name |
Beperminogene perplasmid
|
|||
| Indication | Critical limb ischemia [ICD-11: BD4Y; ICD-9: 459.89] | Phase 3 | [1] | |
| Heart disease [ICD-11: BA41-BA42; ICD-9: 390-429] | Phase 3 | [2] | ||
| Company |
AnGes; Daiichi
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02144610) Safety and Efficacy of Subjects With Critical Limb Ischemia. U.S. National Institutes of Health. | |||
| REF 3 | Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.